Zihai Li named director of Ohio State Institute for Immuno-Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Zihai Li was named director of the Institute for Immuno-Oncology at Ohio State University Comprehensive Cancer Center-James Cancer Hospital.

He comes to Ohio State from the Medical University of South Carolina, where he was a professor and chair of the Department of Microbiology and Immunology, and co-leader of the Center Immunology Program at Hollings Cancer Center.

Li is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. His primary interests are in the mechanisms of immune regulation in cancer. Some of his research focuses on immunological properties of heat shock proteins in cancer immunotherapeutics against cancer by reprogramming the tumor microenvironment, including regulatory T cells, thrombocytes, and unfolded protein response. His work is supported by NIH, including a program project grant from NCI and four RO1s.

Table of Contents

YOU MAY BE INTERESTED IN

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login